SUMMARY
The 2024 ASCO meeting will be remembered for the presentation of the TRANSMET trial, a study in carefully selected patients with definitely unresectable liver metastases, showing that liver transplantation is feasible and leads to better survival. We also learned that thermal ablation is a safe alternative for surgery for small liver metastases in patients with colorectal cancer. The ESOPAC trial is another important study answering a long-standing question on the optimal perioperative treatment in patients with adenocarcinoma of the oesophagus or GEJ junction.
(Belg J Med Oncol 2024;18(5):201–5)
